富瑞特装 reported revenue of ¥1.43B for the period ended 2026-06-30, +4.2% year on year. Net income was ¥0.08B, a 5.7% net margin on a 17.2% gross margin. The largest revenue line is 低温储运应用设备 at 53% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.43B | +4.2% |
| Gross profit | ¥0.25B | — |
| Operating income | ¥0.10B | — |
| Net income | ¥0.08B | -24.9% |
| Gross margin | 17.2% | Net margin 5.7% |
| Revenue Q/Q | -19.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 低温储运应用设备 | ¥0.76B | 52.9% |
| LNG销售及运维服务 | ¥0.42B | 29.1% |
| 重装设备 | ¥0.16B | 10.9% |
| 装卸设备 | ¥0.07B | 4.7% |
| 其他(补充) | ¥0.03B | 2.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.19B | 82.8% |
| R&D | ¥0.04B | 3.1% |
| SG&A | ¥0.09B | 6.1% |
| Tax & other | ¥0.01B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥4.12B |
| Total liabilities | ¥1.45B |
| Shareholders' equity | ¥2.66B |
| Equity / assets | 64.7% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 5% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
拓尔思 ・ 永利股份 ・ 银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies